Cardiol Therapeutics Inc.
CRDL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.16 | 0.00 | 0.21 | 0.17 |
| FCF Yield | -5.49% | -2.98% | -6.22% | -4.36% |
| EV / EBITDA | -11.54 | -17.62 | -10.96 | -17.37 |
| Quality | ||||
| ROIC | -105.00% | -64.23% | -47.52% | -27.89% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.69 | 0.54 | 0.86 | 0.68 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -52.03% | 36.41% | -27.97% | 28.00% |
| Safety | ||||
| Net Debt / EBITDA | 1.16 | 2.36 | 2.75 | 5.38 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -18,633.89 |